Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Clinical trial NCT06856577 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06856577
Sponsor: Adverum Biotechnologies, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD

Start date: 2025-02-28
Primary completion: 2026-12-22
Enrollment: 311

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.